These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34625424)

  • 1. Hyperpolarized Carbon-13 MRI for Early Response Assessment of Neoadjuvant Chemotherapy in Breast Cancer Patients.
    Woitek R; McLean MA; Ursprung S; Rueda OM; Manzano Garcia R; Locke MJ; Beer L; Baxter G; Rundo L; Provenzano E; Kaggie J; Patterson A; Frary A; Field-Rayner J; Papalouka V; Kane J; Benjamin AJV; Gill AB; Priest AN; Lewis DY; Russell R; Grimmer A; White B; Latimer-Bowman B; Patterson I; Schiller A; Carmo B; Slough R; Lanz T; Wason J; Schulte RF; Chin SF; Graves MJ; Gilbert FJ; Abraham JE; Caldas C; Brindle KM; Sala E; Gallagher FA
    Cancer Res; 2021 Dec; 81(23):6004-6017. PubMed ID: 34625424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperpolarized
    Woitek R; McLean MA; Gill AB; Grist JT; Provenzano E; Patterson AJ; Ursprung S; Torheim T; Zaccagna F; Locke M; Laurent MC; Hilborne S; Frary A; Beer L; Rundo L; Patterson I; Slough R; Kane J; Biggs H; Harrison E; Lanz T; Basu B; Baird R; Sala E; Graves MJ; Gilbert FJ; Abraham JE; Caldas C; Brindle KM; Gallagher FA
    Radiol Imaging Cancer; 2020 Jul; 2(4):e200017. PubMed ID: 32803167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging breast cancer using hyperpolarized carbon-13 MRI.
    Gallagher FA; Woitek R; McLean MA; Gill AB; Manzano Garcia R; Provenzano E; Riemer F; Kaggie J; Chhabra A; Ursprung S; Grist JT; Daniels CJ; Zaccagna F; Laurent MC; Locke M; Hilborne S; Frary A; Torheim T; Boursnell C; Schiller A; Patterson I; Slough R; Carmo B; Kane J; Biggs H; Harrison E; Deen SS; Patterson A; Lanz T; Kingsbury Z; Ross M; Basu B; Baird R; Lomas DJ; Sala E; Wason J; Rueda OM; Chin SF; Wilkinson IB; Graves MJ; Abraham JE; Gilbert FJ; Caldas C; Brindle KM
    Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2092-2098. PubMed ID: 31964840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperpolarized
    Chen HY; Aggarwal R; Bok RA; Ohliger MA; Zhu Z; Lee P; Gordon JW; van Criekinge M; Carvajal L; Slater JB; Larson PEZ; Small EJ; Kurhanewicz J; Vigneron DB
    Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):269-276. PubMed ID: 31685983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperpolarized [1-
    Rao Y; Gammon S; Zacharias NM; Liu T; Salzillo T; Xi Y; Wang J; Bhattacharya P; Piwnica-Worms D
    Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22378-22389. PubMed ID: 32839325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
    Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.
    Kim Y; Sim SH; Park B; Lee KS; Chae IH; Park IH; Kwon Y; Jung SY; Lee S; Ko K; Kang HS; Lee CW; Lee ES
    Clin Breast Cancer; 2018 Dec; 18(6):459-467.e1. PubMed ID: 29954674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early progression of breast cancer during neoadjuvant chemotherapy may predict poorer prognoses.
    Myller S; Ipatti P; Jääskeläinen A; Haapasaari KM; Jukkola A; Karihtala P
    Acta Oncol; 2020 Sep; 59(9):1036-1042. PubMed ID: 32394761
    [No Abstract]   [Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy for locally advanced breast cancer in a malaysian tertiary hospital.
    Azrif M; Ibrahim J; Aslan NM; Fong KV; Ismail F
    Asian Pac J Cancer Prev; 2011; 12(1):157-62. PubMed ID: 21517250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
    Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
    Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
    Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
    Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantifying normal human brain metabolism using hyperpolarized [1-
    Grist JT; McLean MA; Riemer F; Schulte RF; Deen SS; Zaccagna F; Woitek R; Daniels CJ; Kaggie JD; Matys T; Patterson I; Slough R; Gill AB; Chhabra A; Eichenberger R; Laurent MC; Comment A; Gillard JH; Coles AJ; Tyler DJ; Wilkinson I; Basu B; Lomas DJ; Graves MJ; Brindle KM; Gallagher FA
    Neuroimage; 2019 Apr; 189():171-179. PubMed ID: 30639333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy.
    Geng SK; Fu SM; Ma SH; Fu YP; Zhang HW
    BMC Cancer; 2021 Jan; 21(1):68. PubMed ID: 33446143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of response evaluation based on breast MRI after neoadjuvant treatment: a retrospective cohort study.
    Bitencourt AGV; Pires BS; Calsavara VF; Negrão EMS; Souza JA; Graziano L; Guatelli CS; Makdissi FB; Sanches SM; Tavares MC; Osório CABT; De Brot M; Marques EF; Chojniak R
    Eur Radiol; 2021 Dec; 31(12):9520-9528. PubMed ID: 34036420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial MRI scans help in assessing early response to neoadjuvant chemotherapy and tailoring breast cancer treatment.
    Fatayer H; Sharma N; Manuel D; Kim B; Keding A; Perren T; Velikova G; Lansdown M; Shaaban AM; Dall B
    Eur J Surg Oncol; 2016 Jul; 42(7):965-72. PubMed ID: 27260848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients.
    Garimella V; Qutob O; Fox JN; Long ED; Chaturvedi A; Turnbull LW; Drew PJ
    Eur J Surg Oncol; 2007 Mar; 33(2):157-61. PubMed ID: 17085007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
    Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
    Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
    Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
    Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.